INS and type 2 diabetes mellitus: In contrast, amelioration of insulin sensitivity by the PPARγ agonists, pioglitazone, and rosiglitazone, is accompanied by an increase in subcutaneous fat mass, but not in visceral fat weight in obese rats [30, 32], and also in the patients with type 2 diabetes [33].